Illumina cuts annual profit forecast as biotech funding woes linger
(Reuters) -Illumina Inc cut annual profit forecast, in a sign that a funding crunch among its biotech and pharmaceutical clients is expected to weigh on sales for its genetic testing tools and diagnostics products. Shares were down nearly 6% in extended trading on Wednesday. Rising interest rates have squeezed funding for drug development and research…
